国家: 美国
语言: 英文
来源: NLM (National Library of Medicine)
LAMOTRIGINE (UNII: U3H27498KS) (LAMOTRIGINE - UNII:U3H27498KS)
State of Florida DOH Central Pharmacy
ORAL
PRESCRIPTION DRUG
Adjunctive Therapy: Lamotrigine tablets, USP are indicated as adjunctive therapy for the following seizure types in patients ≥2 years of age: - partial seizures - primary generalized tonic-clonic seizures. - generalized seizures of Lennox-Gastaut syndrome Monotherapy: Lamotrigine tablets, USP are indicated for conversion to monotherapy in adults (≥16 years of age) with partial seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug (AED). Safety and effectiveness of lamotrigine tablets, USP have not been established (1) as initial monotherapy; (2) for conversion to monotherapy from AEDs other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate; or (3) for simultaneous conversion to monotherapy from 2 or more concomitant AEDs. Lamotrigine tablets, USP are indicated for the maintenance treatment of Bipolar I Disorder to delay the time to occurrence of mood episodes (depression, mania, hypomania, mixed episode
Lamotrigine Tablets, USP 25-mg White to off white, round shape, flat face beveled edge, uncoated tablets debossed with "45" on one side and break line on other side. Lamotrigine Tablets, USP 100-mg White to off white, round shape, flat face beveled edge, uncoated tablets debossed with "1047" on one side and break line on other side. Lamotrigine Tablets, USP 150-mg White to off white, round shape, flat face beveled edge, uncoated tablets debossed with "1048" on one side and break line on other side. Lamotrigine Tablets, USP 200-mg White to off white, round shape, flat face beveled edge, uncoated tablets debossed with "1049" on one side and break line on other side. They are supplied by State of Florida DOH Central Pharmacy as follows: Storage Store at 20° - 25°C (68° - 77°F); excursions permitted to 15° - 30°C (59° - 86°F). [See USP Controlled Room Temperature].
Abbreviated New Drug Application
LAMOTRIGINE - LAMOTRIGINE TABLET State of Florida DOH Central Pharmacy ---------- MEDICATION GUIDE Lamotrigine Tablets, USP Rx Only Read this Medication Guide before you start taking lamotrigine and each time you get a refill. There may be new information. This information does not take the place of talking with your healthcare provider about your medical condition or treatment. If you have questions about lamotrigine, ask your healthcare provider or pharmacist. What is the most important information I should know about lamotrigine? 1. Lamotrigine may cause a serious skin rash that may cause you to be hospitalized or to stop lamotrigine; it may rarely cause death. There is no way to tell if a mild rash will develop into a more serious reaction. These serious skin reactions are more likely to happen when you begin taking lamotrigine, within the first 2 to 8 weeks of treatment. But it can happen in people who have taken lamotrigine for any period of time. Children between 2 to 16 years of age have a higher chance of getting this serious skin reaction while taking lamotrigine . The risk of getting a serious skin rash is higher if you: • take lamotrigine while taking valproate (valproic acid or divalproex sodium) • take a higher starting dose of lamotrigine than your healthcare provider prescribed • increase your dose of lamotrigine faster than prescribed. Lamotrigine can also cause other types of allergic reactions or serious problems which may affect organs and other parts of your body like the liver or blood cells. You may or may not have a rash with these types of reactions. Call your healthcare provider right away if you have any of the following: • a skin rash • hives • fever • swollen lymph glands • painful sores in the mouth or around your eyes • swelling of your lips or tongue • yellowing of your skin or eyes • unusual bruising or bleeding • severe fatigue or weakness • severe muscle pain • frequent infections These symptoms may be the first signs of a serious skin reaction. A hea 阅读完整的文件
LAMOTRIGINE - LAMOTRIGINE TABLET STATE OF FLORIDA DOH CENTRAL PHARMACY ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE LAMOTRIGINE TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR LAMOTRIGINE TABLETS LAMOTRIGINE TABLETS, USP INITIAL U.S. APPROVAL: 1994 WARNING: SERIOUS SKIN RASHES _SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._ CASES OF LIFE-THREATENING SERIOUS RASHES, INCLUDING STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS, AND/OR RASH-RELATED DEATH, HAVE BEEN CAUSED BY LAMOTRIGINE. THE RATE OF SERIOUS RASH IS GREATER IN PEDIATRIC PATIENTS THAN IN ADULTS. ADDITIONAL FACTORS THAT MAY INCREASE THE RISK OF RASH INCLUDE (5.1): COADMINISTRATION WITH VALPROATE EXCEEDING RECOMMENDED INITIAL DOSE OF LAMOTRIGINE EXCEEDING RECOMMENDED DOSE ESCALATION OF LAMOTRIGINE BENIGN RASHES ARE ALSO CAUSED BY LAMOTRIGINE; HOWEVER, IT IS NOT POSSIBLE TO PREDICT WHICH RASHES WILL PROVE TO BE SERIOUS OR LIFE THREATENING. LAMOTRIGINE SHOULD BE DISCONTINUED AT THE FIRST SIGN OF RASH, UNLESS THE RASH IS CLEARLY NOT DRUG RELATED. (5.1) RECENT MAJOR CHANGES Warnings and Precautions, Multiorgan Hypersensitivity Reactions and Organ Failure (5.2) August 2011 INDICATIONS AND USAGE Lamotrigine, USP is an antiepileptic drug (AED) indicated for: EPILEPSY—ADJUNCTIVE THERAPY IN PATIENTS ≥2 YEARS OF AGE: (1.1) partial seizures. primary generalized tonic-clonic seizures. generalized seizures of Lennox-Gastaut syndrome. EPILEPSY—MONOTHERAPY IN PATIENTS ≥16 YEARS OF AGE: conversion to monotherapy in patients with partial seizures who are receiving treatment with carbamazepine, phenobarbital, phenytoin, primidone, or valproate as the single AED. (1.1) BIPOLAR DISORDER IN PATIENTS ≥18 YEARS OF AGE: maintenance treatment of Bipolar I Disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy. (1.2) DOSAGE AND ADMINISTRATION Dosing is based on concomitant medications, indicatio 阅读完整的文件